Revosimeline

A muscarinic receptor agonist

Revosimeline
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Revosimeline is a pharmaceutical drug that acts as a selective muscarinic receptor agonist. It was primarily investigated for its potential use in treating xerostomia, commonly known as dry mouth, which is often a side effect of radiation therapy in head and neck cancer patients or a symptom of Sjögren's syndrome.

Pharmacology

Revosimeline is a selective agonist for the M1 and M3 subtypes of muscarinic receptors. These receptors are part of the G protein-coupled receptor family and are involved in various physiological functions, including the modulation of salivary gland secretion. By stimulating these receptors, revosimeline increases the production of saliva, thereby alleviating symptoms of xerostomia.

Mechanism of Action

The mechanism of action of revosimeline involves its binding to the muscarinic receptors, particularly the M3 subtype, which is predominantly expressed in the salivary glands. Upon activation, these receptors initiate a cascade of intracellular events that lead to increased secretion of saliva. This action mimics the natural stimulation of salivary glands by the parasympathetic nervous system.

Clinical Development

Revosimeline was developed with the intention of providing relief for patients suffering from dry mouth due to various medical conditions. Clinical trials were conducted to evaluate its efficacy and safety profile. However, despite initial promising results, the development of revosimeline was eventually discontinued. The reasons for discontinuation included challenges in demonstrating a significant clinical benefit over existing treatments and potential side effects.

Side Effects

As with many drugs that act on the cholinergic system, revosimeline can cause side effects related to its action on muscarinic receptors. Common side effects observed in clinical trials included sweating, nausea, and diarrhea. These effects are consistent with the activation of muscarinic receptors in various tissues throughout the body.

Related Pages

• Muscarinic receptor
• Xerostomia
• Sjögren's syndrome
• G protein-coupled receptor